Medical Oncology 3 – Head and Neck Cancers
Milano
Via Giacomo Venezian, 1, 20133 Milano MI
Associate Professor Licitra Lisa Francesca Linda
Direttore di struttura complessa
Typology: Clinical Area, Complex Structure
The aim of the Medical Oncology 3 – Head and Neck Cancer Unit is to ensure the most appropriate diagnostic, therapeutic and care pathway, based on a multidisciplinary approach and the latest scientific evidence, for patients with cancer of the head and neck. Although the condition treated in this unit is classified as ‘rare’, we are actively involved in numerous national and international research protocols that enable patients to access the best available treatments and the most innovative drugs for the specific type of disease they are suffering from.
The centre’s services are divided into outpatient services and inpatient services.
Outpatient services are available every day from 8.30 am to 4.00 pm; during these hours, we see patients currently undergoing treatment, as well as those who have completed their treatment and are attending for follow-up appointments.
In addition, there are 6 slots available each week for ‘Initial Oncology Consultations’. These services are provided under the National Health Service (NHS) and can be booked by telephone on (+39) 02 2390 2150 (Mon–Fri 9.00–10.00) or by email at amo@istitutotumori.mi.it
For all types of booking (including telephone bookings), you must have your health card, a medical prescription stating the clinical referral, and your tax code.
Once the appointment has been scheduled, patients are asked to go to the CUP (Central Appointment Service) upon arrival at the Institute to register. The administrative staff will provide directions to the consultation room.
In line with the multidisciplinary approach required by this condition, two initial consultation clinics are held in collaboration with colleagues from Radiotherapy, Maxillofacial Surgery and Otorhinolaryngology, on Tuesdays and Thursdays respectively from 2.00 pm to 4.00 pm. These services are also provided under the National Health Service (NHS) and can be booked by telephone on (+39) 02 2390 1. The outpatient consultation is the first point of contact with the facility.
The inpatient ward is located on the 3rd floor of Block F and has 7 beds. The ward consists of twin rooms with en-suite bathrooms. Inpatient care is reserved for patients requiring specific medical treatments and/or supportive care during integrated chemoradiotherapy and throughout all stages of the disease.
Medical treatment of
- locally advanced head and neck cancers
- recurrent/metastatic head and neck cancers
- advanced non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, carcinomas of the skin appendages)
- Advanced malignant thyroid tumours
- Mail: amo@istitutotumori.mi.it
- Tel: 0223902150
Note: Monday to Friday (working days) from 9:00 a.m. to 10:00 a.m.
Visiting hours for inpatients
- Weekdays: 4:30 p.m. to 6:30 p.m.
- Public holidays: 10:00 a.m. to 11:00 a.m. and 4:30 p.m. to 6:30 p.m.
NB: only one visitor per hospitalized patient is allowed
Access hours for medical representatives: by appointment
Professoressa Associata Licitra Lisa Francesca Linda
Direttore di struttura complessa
Dott. Alfieri Salvatore
Medical Director
Dott.ssa Bergamini Cristiana
Medical Director
Dott. Cavalieri Stefano
Medical Director
Dott.ssa Colombo Elena
Medical Director
Dott.ssa Nuzzolese Imperia
Medical Director
Dott.ssa Ottini Arianna
Medical Director
Segreteria scientifica:
- Francesca Mazzetti
- Luca Terreni
Segreteria clinico-amministrativa:
- Paola Maggioni
Data Center:
- Francesca Di Bernardo
- Francesca Donno
- Federica Fabiano
- Antonello Manocchio
- Mariateresa Tangari
A multicenter, randomized, double-blind, Phase II/III study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab as first-line treatment in patients with recurrent or metastatic PD-L1–positive head an
A multicenter, randomized, double-blind, Phase II/III study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab as first-line treatment in patients with recurrent or metastatic PD-L1–positive head an
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AV-299 in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing
A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Ce
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Pr
A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) p
Circulating EBV-DNA changes in tailoring treatment of locally advanced nasopharyngeal carcinoma: the phase 2 trial INTERLAYER
Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)
Neoadjuvant pembrolizumab plus chemotherapy in locally advanced sinonasal carcinoma (NeoPeSino)
Artificial intelligence-based analysis of longitudinal breath profiles of head and neck cancer patients’ survivors
Big Data Models and Intelligent tools for Quality of Life monitoring and participatory empowerment of head and neck cancer survivors (BD4QoL)
Matching primary tumor and blood gene expression analysis of HPV-negative squamous head and neck cancers (BIOMATCH - Head and Neck) - PNRR-MCNT1-2023-12377359
Optimizing biomarkers of immunotherapy response in clinical studies summarizing head and neck cancer natural history
Digital twins for radiotherapy
European Reference Network on Rare Adult Solid Cancers "EURACAN": entering phase II - EURACAN23-27
Exploiting Artificial Intelligence-based tools for analysis of clinical breathomics data
Intelligent Ecosystem to improve the governance, the sharing and the re-use of health Data for Rare Cancers - IDEA4RC
Last update: 23/04/2026